^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L747S

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2ms
    Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report. (PubMed, Oncol Lett)
    The present study describes the case of a patient diagnosed with lung adenocarcinoma (LUAD) carrying two rare EGFR exon 18 indel/G719C and exon 19 L747S mutations, in which persistent lesion shrinkage was exhibited within 16 months of osimertinib treatment. Given the paucity of clinical trials for the treatment of LUAD harboring complex EGER mutations, the present detailed case description may provide clinicians with effective clinical experience in treating patients.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR G719C • EGFR L747S
    |
    Tagrisso (osimertinib)
    over1year
    Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial (IASLC-WCLC 2023)
    In this study, we observed the clinical benefit of 240mg Lazertinib in the treatment of naïve EGFR uncommon mutants. Among the mutations, G719X and L861Q showed promising outcomes, which are aligned with preclinical data. The safety profile was consistent with registry trials, indicating the necessity of further exploration for clinical efficacy in uncommon EGFR mutations on a larger scale.
    Clinical • P2 data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747S • EGFR E709A
    |
    Lazcluze (lazertinib)
    over1year
    Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. (PubMed, Am J Cancer Res)
    Mechanistically, nuclear EGFR signaling is required for sustaining nuclear activated STAT3, but not for Erk. These findings suggest that EGFR functions are compartmentalized and that nuclear EGFR signaling plays a crucial role in tumor malignant phenotypes, leading to tumorigenesis in human cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • STAT3 (Signal Transducer And Activator Of Transcription 3) • NES (Nestin)
    |
    EGFR mutation • EGFR L747P • EGFR L747S
    over2years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Trial primary completion date: Mar 2022 --> Oct 2022
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    over2years
    An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. (PubMed, Nat Cancer)
    We further uncover that EGFR homo- or heterodimerization with other ERBB family members, as well as the EGFR L747S mutation, confers resistance to JBJ-09-063, but not to ATP-competitive EGFR TKIs. Overall, our studies highlight the potential clinical utility of JBJ-09-063 as a single agent or in combination with EGFR TKIs to define more effective strategies to treat EGFR-mutant lung cancer.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • EGFR C797S • EGFR T790M + EGFR C797S • EGFR L747S
    over2years
    LU21-16: Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Yonsei University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747S • EGFR E709A
    |
    Lazcluze (lazertinib)
    almost4years
    A case treated with crizotinib after secondary MET amplification of a double-rare L747S and L719S EGFR mutation pulmonary sarcomatoid carcinoma. (PubMed, Ann Oncol)
    No abstract available
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification • EGFR G719S • EGFR L747S
    |
    Xalkori (crizotinib)
    almost4years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Recruiting, Shanghai Chest Hospital | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)
    almost4years
    [VIRTUAL] Molecular Characteristics and Response to EGFR TKIs of EGFR L747 Position Mutation in Lung Cancer Patients. (IASLC-WCLC 2020)
    As for patients treated with EGFR TKIs, three EGFR L747P patients achieved partial response through afatinib treatment, and two EGFR L747S patient achieved progressive disease to icotinib treatment. Figure 1. Chest computed tomography images before (at baseline) and after treatment with afatinib in patients 2.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR G719X • EGFR positive • EGFR L747P • EGFR L747S
    |
    Gilotrif (afatinib) • Conmana (icotinib)
    over4years
    Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Shanghai Chest Hospital
    Clinical • New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
    |
    Vizimpro (dacomitinib)